Histone Deacetylase Inhibitors: Current Status in Treatment of Leukemia

  • Avineesh Singh Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur495 009, (C.G.) India.
  • Vijay K Patel Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur495 009, (C.G.) Indi
  • Deepak K Jain Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur495 009, (C.G.) India.
  • Prabodh C Sharma Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra136 119, (Haryana) India
  • Arun K Gupta B.P.S. Mahila Vishwavidyalaya, Khapur-Kalan,Sonepat-131001, (Haryana) India.
  • Ajay K Sharma Department of Pharmacy, G.S.V.M., Medical College, Kanpur-208002, (UP) India
  • Harish Rajak Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur495 009, (C.G.) India.

Abstract

Leukemia, one of leading cancer occurs by the acquisition of gene mutations that confer deregulated proliferation and impaired differentiation. Several histone decaetylase inhibitors (HDACi) have exhibited significant protection against the growth of tumor cells in vitro as well as in vivo. Thus it is anticipated that some HDACi could be efficient anti-leukemic drugs. Here, we summarize the current status of different types of HDACi and their clinical role in therapy of different types of leukemia. 

Keywords: Leukemia, HDACi, Hydroxamates, Benzamides, Cyclic peptides, Short chain fatty acids.
Statistics
26 Views | 29 Downloads
How to Cite
Singh, A., V. K. Patel, D. K. Jain, P. C. Sharma, A. K. Gupta, A. K. Sharma, and H. Rajak. “Histone Deacetylase Inhibitors: Current Status in Treatment of Leukemia”. Current Research in Pharmaceutical Sciences, Vol. 3, no. 4, Dec. 2013, pp. 102-7, http://crpsonline.com/index.php/crps/article/view/106.
Section
Review Articles

Most read articles by the same author(s)